Astrion drew more interest than AstraGin at NuLiv Science's Bangkok booth

NuLiv Science arrived at Vitafoods Asia 2026 in Bangkok expecting AstraGin, its absorption ingredient, to be the draw. Visitors asked instead about Astrion, the company's collagen-building botanical, a NuLiv Science speaker said in a MarketScale Studio segment recorded at the show.

The show ran September 2 to 4, 2026 at the Queen Sirikit National Convention Center, according to an August 2026 preview from DataM Intelligence. NuLiv came with fresh evidence for both ingredients the region asked about: a 150-person Astrion skin trial published in the journal Cosmetics in June 2025, and a Senactiv muscle study announced on July 8, 2026, eight weeks before the doors opened. The company said on the recording that it came because the Asian market keeps expanding and that it now works with sales teams in Malaysia, Indonesia and Bangkok.

For a formulator in Malaysia, Indonesia or Thailand picking an active for a beauty launch, that booth result comes with a 150-person trial behind it, a collagen market that still trails North America, and a Thai registration path that begins with a local importer.

Collagen on every shelf changed the booth conversation

Richard Wang, chief executive of NuLiv Science, made the same positioning argument a year earlier: a plant-based skin-health compound helps brands differentiate their collagen and skin-health products, he said in a July 2025 press release. Where collagen itself is on every shelf, the offer becomes a botanical that pushes the customer's own skin to make more of it.

The company's list of what customers asked about ran to vitamins, probiotics and longevity products. Its own most popular ingredients at the show were AstraGin, because it fits into many product types, astaxanthin, a red carotenoid pigment, on the strength of the region's beauty focus, and InnoSlim for weight management, the speaker said. Two of the three tie back to the same beauty and aging concern that put Astrion ahead.

Two Astragalus blends, two different jobs

AstraGin and Astrion share a root. Both are built on Astragalus membranaceus, a herb from Traditional Chinese Medicine, but the second plant in each blend sends them in different directions.

AstraGin pairs Astragalus with Panax notoginseng root and is intended to improve the body's absorption of amino acids, glucose and vitamins, Nutritional Outlook reported in April 2012, when the trade publication covered the ingredient's GRAS status. GRAS, short for generally recognized as safe, is the US designation that lets a substance be used in food without premarket approval once qualified experts agree on its safety; AIBMR Life Sciences of Puyallup, Washington issued the determination. A 28-day rat study at 100, 300 and 1,000 times the suggested human dose found no mortality or clinical health changes, according to the same report.

In NuLiv's account, AstraGin moves nutrients across the gut wall and Astrion pushes skin cells to make collagen. The second job has a published mechanism behind it.

Astrion, which the release and the paper abbreviate as ACS, combines Astragalus membranaceus saponins with those of Centella asiatica. Saponins are the soapy plant compounds that give both herbs their activity. The Cosmetics paper, written by researchers at Kaohsiung Medical University and Chia Nan University of Pharmacy and Science in Taiwan, lays out how the two act on skin.

Astragalosides, the key active compounds in Astragalus, protect skin fibroblasts, the cells that manufacture collagen, from ultraviolet A damage, the paper says, citing earlier research. They do this by lowering MMP-1, an enzyme that breaks collagen down, and by raising TIMP-1, a protein that blocks that enzyme, and TGF-beta 1, a growth signal that tells cells to build tissue. Centella's asiaticoside and madecassoside stimulate collagen production and raise hyaluronic acid, the humectant that holds water in the skin layers, according to the same review of prior work.

Earlier laboratory work cited in the paper found the combination increased uptake of proline and glucosamine, two building blocks of collagen and connective tissue, in human keratinocytes, the main cells of the outer skin layer, and in dermal fibroblasts. That is the basis for the speaker's claim that Astrion grows collagen and hyaluronic acid. The trial measured total collagen content; the collagen one and collagen three framing is the company's own.

Luis Gonzalez, NuLiv's vice president of sales, walked through the whole portfolio in a sponsored post on PricePlow in May 2026, and described a 2026 AstraGin whey protein study that NuLiv credits with 12% to 14% improvements in amino acid uptake and a reduction in zonulin, a protein marker of gut permeability, across three age groups. AstraGin turns up in pre-workouts, protein powders, energy drinks and gut health supplements, the post said. Bangkok did not change that; it changed which ingredient opened the conversation.

A 150-person trial sits behind the collagen pitch

The trial NuLiv announced on July 9, 2025 is the largest human study the company has run, Wang said in the press release. Cosmetics published it on June 20, 2025 as a randomized, double-blind, placebo-controlled study of 150 healthy adults aged 20 or older with no history of chronic skin disease. Double-blind means neither the participants nor the researchers measuring them knew who received the active and who received the placebo.

Participants were split into six groups: topical cream, oral capsules and a combination of both, each paired with a matching placebo. Skin brightness, moisture, elasticity, melanin, pore count, texture and collagen content were measured over four to 12 weeks, the paper's abstract says.

Oral Astrion alone raised skin collagen content 13.2% over 12 weeks in NuLiv Science's 150-person trial, the company said in its July 2025 release. The same oral group saw an 18.5% drop in the texture measure, which the paper counts as smoother skin, and 10.5% fewer pores against baseline. Four weeks of topical use produced a 2.5% brightness gain, 6.5% better elasticity, a 5.2% drop in melanin, 10.6% fewer pores and 8.7% more collagen, all statistically significant, according to the paper.

The combined group did best. Brightness rose 4.2%, moisture 12.9%, elasticity 9.0% and collagen 13.7%, while melanin fell 8.2% and pore count fell 28.5%, the release said. For a supplement brand the oral arm is the number that matters; for a cosmetics house it is the topical arm, and the company sells the same ingredient into both.

Probiotics for pets and children fill the Asian brief

Asked what differed from the US market, the speaker's first answer was probiotics, sorted by health function. The company described strains sold for pet weight loss, for children's health, for gut health and for women's health. That degree of segmentation was the difference the speaker chose to lead with.

DataM's preview supports the read. Biogrowing planned to present probiotic strains tied to digestion, metabolic regulation, women's health and emotional wellbeing; Glac Biotech brought postbiotics, the non-living byproducts of probiotic bacteria; and Lallemand Bio-Ingredients was launching a probiotic built around the gut-muscle axis, the link between gut bacteria and muscle, according to the August 2026 article. Balchem was presenting research on cognitive health in post-menopausal women, and Lallemand had clinical work on menstrual health and pregnancy support.

Thailand's approved probiotic list ran to five strains as of February 2026, according to regulatory consultancy DeeMED Consulting. For anyone hoping to import the pet or children's strains the speaker described, that list is the first gate, and a strain outside it needs its own approval before a label can carry it.

DataM's list of show themes also bounds NuLiv's thesis. The preview named healthy longevity, gut and microbiome health, women's health, metabolic wellness, beauty-from-within and botanicals as the themes shaping Asia-Pacific development, and the exhibitors it named came with probiotics, Ayurvedic botanicals, omega-3 sourcing and women's health research. Beauty-from-within was one theme of six; the weight NuLiv gives it came from booth traffic rather than a survey.

Senactiv's longevity claim has an 11-woman muscle study behind it

Senactiv is NuLiv's patented compound built around ginsenoside Rg1, one of the active molecules in ginseng root, the company said in a press release distributed by Newswise on July 8, 2026. The release announced a study in the Journal of Ginseng Research whose title describes a senolytic effect, meaning the clearing of senescent cells, the worn-out cells that stop dividing but linger in tissue. The idea is that hard exercise already prompts muscle to clear those cells, and the compound amplifies the response.

The design is specific. Eleven women aged 60 to 73 performed four sets of seated leg press at 70% of their one-repetition maximum, the heaviest weight they could lift once, one hour after taking either Senactiv or a placebo, in a randomized, double-blind, placebo-controlled crossover trial in which each woman completed both conditions. Researchers took muscle biopsies at baseline and 24 hours after exercise, according to the release.

Adding Senactiv doubled muscle-recovery stem cells after leg presses in the 11 women, NuLiv announced in July 2026. Cellular energy levels, a measure of how well mitochondria, the cell's power plants, are working, also doubled, where exercise alone had limited effect on either marker, the company said. Exercise alone produced a significant drop in estradiol, the main female sex hormone, while the Senactiv group held pre-exercise estradiol and saw progesterone, a second sex hormone, double.

Eleven participants is a small sample, and NuLiv did not frame it as a final word. Wang said in the release that there was more work to do, especially for active aging and women's health, and that the company was already planning the next study. Which of these findings the Bangkok talk drew on, the company did not say.

North America still buys more collagen than Asia

The speaker's picture of collagen on every shelf needs a number beside it. North America took 37.95% of collagen supplement revenue in 2025 while Asia-Pacific grows fastest, Mordor Intelligence estimates in a 2026 report. The firm puts the Asia-Pacific growth rate at 11.65% a year through 2031 and lists North America as the largest market.

That is the complication for the thesis. Asian consumers may prioritize beauty and anti-aging over the categories that dominate US shelves, but the region is not yet outbuying the US in collagen; it is catching up faster. Mordor does not size Southeast Asia on its own, so the Malaysian, Indonesian and Thai markets the company is targeting cannot be measured from that report.

Thailand's Food Act governs who can import the ingredient

Selling a dietary supplement ingredient into Thailand runs through the Food Act B.E. 2522 (1979), Ministry of Public Health notifications and ASEAN frameworks for traditional medicines and health supplements, according to DeeMED Consulting, a regulatory consultancy that publishes guidance for foreign manufacturers on its site. The act sets the framework under which the Thai Food and Drug Administration classifies and registers a product before sale.

A foreign brand needs a Thai importer holding an Orr.7 import license before a product can enter the country, DeeMED advises. Manufacturers are held to GMP 420, Thailand's good manufacturing practice standard, the rulebook for how a factory must make, test and document a supplement, and only certain bodies may certify against it. Health claims come from a positive list, meaning a label may say only what the regulator has already approved.

Classification comes before registration. DeeMED published a June 2026 guide on whether a traditional herbal supplement registers as a food or as a traditional medicine, the question a Traditional Chinese Medicine botanical like Astrion or Senactiv faces first, and a separate June 2026 guide on where cosmeceuticals and functional foods fall under Thai rules, a boundary that matters for an ingredient sold both as a cream and a capsule. In March 2026 Thailand removed pre-submission laboratory testing for food supplement registration, the consultancy reported, taking one step out of the dossier.

The consultancy also published a June 2026 guide on ASEAN traditional medicine harmonization, the regional effort to align product rules across the bloc that includes Thailand, Malaysia and Indonesia. For a supplier working with sales teams in all three, that alignment decides how much of a Thai dossier travels.

Match the ingredient to the demographic, the company says

The advice describes what happened at NuLiv's own booth. The company brought its broadest ingredient expecting it to lead, watched the traffic, and let a skin ingredient open the conversation instead.

The next dated marker on NuLiv's calendar is the follow-up Senactiv study Wang said in July 2026 the company was already planning, a second data set for the longevity talk it gave in Bangkok. Beyond that, Mordor's 11.65% Asia-Pacific forecast runs to 2031, the schedule on which the region is expected to close on North America in collagen.